Search Result
Results for "
muscle disorders
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P10476
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 2 (compd 2) is a myostatin inhibitor with a Kd of 35.9 nM. Myostatin inhibitory peptide 2 can be used for researches of muscle atrophic disorders .
|
-
-
- HY-W012734
-
H-HoPro-OH
|
Endogenous Metabolite
|
Metabolic Disease
|
L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .
|
-
-
- HY-108283
-
AA 149; Supacal
|
Others
|
Inflammation/Immunology
|
Trepibutone (AA 149) increases secretion of bile and pancreatic juice, and accelerates flaccidity of the smooth muscle in the gastrointestinal tract. Trepibutone can be used for the research of cholecystitis and functional gastrointestinal disorders .
|
-
-
- HY-122697
-
-
-
- HY-B1139
-
|
Apoptosis
|
Neurological Disease
|
Tolperisone hydrochloride is a centrally acting muscle relaxant studied in neurological disorders causing pathological rhabdomyosclerosis (pyramidal tract injury, multiple sclerosis, myelopathy, encephalomyelitis), spastic paralysis, and other muscle dystonia-related Encephalopathy. Tolperisone hydrochloride also has antiviral activity .
|
-
-
- HY-B0740
-
MK130 hydrochloride
|
5-HT Receptor
Parasite
|
Infection
Neurological Disease
|
Cyclobenzaprine (MK130) hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Additionally, Cyclobenzaprine hydrochloride has antiprotozoal activity. Additionally, Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases
|
-
-
- HY-W012734R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
L-Pipecolic acid (Standard) is an analytical standard of L-Pipecolic acid. This product is used for research and analytical applications. L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases .
|
-
-
- HY-108283R
-
AA 149 (Standard); Supacal (Standard)
|
Calcium Channel
Reference Standards
|
Inflammation/Immunology
|
Trepibutone (Standard) is the analytical standard of Trepibutone. This product is intended for research and analytical applications. Trepibutone (AA 149) increases secretion of bile and pancreatic juice, and accelerates flaccidity of the smooth muscle in the gastrointestinal tract. Trepibutone can be used for the research of cholecystitis and functional gastrointestinal disorders .
|
-
-
- HY-122991
-
|
Histone Methyltransferase
|
Neurological Disease
|
Prospasmine hydrochloride is an anticholinergic drug that has the activity of inhibiting glandular secretions and relaxing smooth muscles. Prospasmine hydrochloride is mainly used to inhibit certain types of gastrointestinal disorders. Prospasmine hydrochloride helps relieve pain caused by smooth muscle spasms. Prospasmine hydrochloride is also used as an anesthetic adjuvant in some cases .
|
-
-
- HY-P10476A
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 2 (compd 2) TFA is a myostatin inhibitor with a Kd of 35.9 nM. Myostatin inhibitory peptide 2 TFA can be used for researches of muscle atrophic disorders .
|
-
-
- HY-B1139R
-
|
Apoptosis
|
Neurological Disease
|
Tolperisone (hydrochloride) (Standard) is the analytical standard of Tolperisone (hydrochloride). This product is intended for research and analytical applications. Tolperisone hydrochloride is a centrally acting muscle relaxant studied in neurological disorders causing pathological rhabdomyosclerosis (pyramidal tract injury, multiple sclerosis, myelopathy, encephalomyelitis), spastic paralysis, and other muscle dystonia-related Encephalopathy. Tolperisone hydrochloride also has antiviral activity .
|
-
-
- HY-B0740R
-
MK130 hydrochloride (Standard)
|
5-HT Receptor
|
Neurological Disease
|
Cyclobenzaprine (MK130) hydrochloride (Standard) is the analytical standard of Cyclobenzaprine (MK130) hydrochloride. This product is intended for research and analytical applications. Cyclobenzaprine hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Additionally, Cyclobenzaprine hydrochloride has antiprotozoal activity. Additionally, Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases
|
-
-
- HY-W012980
-
|
Endogenous Metabolite
AMPK
PKA
|
Metabolic Disease
|
Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .
|
-
-
- HY-B0740S3
-
MK130-d3-1 hydrochloride
|
Isotope-Labeled Compounds
5-HT Receptor
Parasite
|
Infection
Neurological Disease
|
Cyclobenzaprine-d3-1 hydrochloride (MK130-d3-1 hydrochloride) is the deuterium labeled Cyclobenzaprine hydrochloride (HY-B0740). Cyclobenzaprine (MK130) hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Additionally, Cyclobenzaprine hydrochloride has antiprotozoal activity. Additionally, Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases
|
-
-
- HY-P10242
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 7 is a 23 amino acids peptide, which is derived from amino acids 21 to 43 of the mouse myostatin prodomain. Myostatin inhibitory peptide 7 inhibits myostatin with a Kd of 29.7 nM. Myostatin inhibitory peptide 7 can be used for researches of muscle atrophic disorders .
|
-
-
- HY-P10242A
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 7 TFA is a 23 amino acids peptide, which is derived from amino acids 21 to 43 of the mouse myostatin prodomain. Myostatin inhibitory peptide 7 TFA inhibits myostatin with a Kd of 29.7 nM. Myostatin inhibitory peptide 7 TFA can be used for researches of muscle atrophic disorders .
|
-
-
- HY-P2436
-
|
Neurokinin Receptor
|
Neurological Disease
|
L-659837 is a NK2 receptor antagonist, and can antagonize GR 64349 (HY-P1278)-induced contraction. L-659837 can be used for study of urinary bladder disorders .
|
-
-
- HY-15847
-
HS38
3 Publications Verification
|
DAPK
|
Cardiovascular Disease
|
HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with Kds of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders .
|
-
-
- HY-W012980R
-
|
Endogenous Metabolite
AMPK
PKA
|
Metabolic Disease
|
Isovaleric acid (Standard) is the analytical standard of Isovaleric acid. This product is intended for research and analytical applications. Isovaleric acid is an oral active short-chain fatty acid that inhibits osteoclast differentiation by stimulating AMPK phosphorylation and promotes colonic smooth muscle relaxation by activating the cAMP/PKA pathway. Isovaleric acid can be used in research on skeletal diseases (such as osteoporosis) and intestinal disorders .
|
-
-
- HY-W153897
-
|
Adrenergic Receptor
|
Metabolic Disease
|
N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .
|
-
-
- HY-W153897R
-
|
Adrenergic Receptor
|
Metabolic Disease
|
N-Methyltyramine (Standard) is the analytical standard of N-Methyltyramine. This product is intended for research and analytical applications. N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .
|
-
-
- HY-173527
-
|
Others
|
Metabolic Disease
|
PSSI-51 is an orally active, peripherally selective inhibitor of succinyl-CoA:3-ketoacid-CoA transferase (SCOT). PSSI-51 inhibits SCOT activity in peripheral tissues (such as muscle and kidney) but does not affect SCOT activity in brain tissue. PSSI-51 reduces ketone body oxidation by inhibiting SCOT, thereby improving obesity-related hyperglycemia. PSSI-51 can be used in the study of type 2 diabetes (T2D) and has the potential to improve obesity-related metabolic disorders .
|
-
-
- HY-137312A
-
SKF 40383-A hydrochloride
|
Adrenergic Receptor
|
Inflammation/Immunology
|
Carbuterol (SKF 40383-A) hydrochloride is a selective β2-adrenergic receptor agonist that primarily targets bronchial smooth muscle, exhibiting significant bronchodilatory and anti-allergic activity. Carbuterol hydrochloride can directly inhibit the immunologically induced release of histamine and slow-reacting substance of anaphylaxis (SRS-A), thereby alleviating allergic responses. In addition, it exerts mild β1-mediated cardiac stimulation and is applicable to studies related to respiratory and immune-related diseases such as asthma and allergic disorders .
|
-
-
- HY-108433
-
Carnitine palmitoyltransferase 2
|
Apoptosis
MDM-2/p53
|
Metabolic Disease
Cancer
|
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .
|
-
-
- HY-B0380A
-
|
Opioid Receptor
Toll-like Receptor (TLR)
Calcium Channel
Potassium Channel
IRAK
ERK
JNK
NF-κB
Akt
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
-
- HY-B0380
-
|
Opioid Receptor
Toll-like Receptor (TLR)
Calcium Channel
Potassium Channel
IRAK
ERK
JNK
NF-κB
Akt
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
-
- HY-B0380S2
-
|
Isotope-Labeled Compounds
Opioid Receptor
Toll-like Receptor (TLR)
Calcium Channel
Potassium Channel
IRAK
ERK
JNK
NF-κB
Akt
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Trimebutine-d3 hydrochloride is deuterium labeled Trimebutine hydrochloride. Trimebutine hydrochloride is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine hydrochloride inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine hydrochloride also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine hydrochloride also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine hydrochloride also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
-
- HY-B0380S1
-
|
Isotope-Labeled Compounds
Opioid Receptor
Toll-like Receptor (TLR)
Calcium Channel
Potassium Channel
IRAK
ERK
JNK
NF-κB
Akt
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Trimebutine-d5 fumarate is deuterium labeled Trimebutine fumarate. Trimebutine fumarate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine fumarate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine fumarate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine fumarate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine fumarate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
-
- HY-B0380AR
-
|
Reference Standards
Opioid Receptor
Apoptosis
Potassium Channel
NF-κB
Akt
IRAK
JNK
Toll-like Receptor (TLR)
ERK
Calcium Channel
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Trimebutine maleate (Standard) is the analytical standard of Trimebutine maleate (HY-B0380A). This product is intended for research and analytical applications. Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
-
- HY-B0380R
-
|
Opioid Receptor
Toll-like Receptor (TLR)
Calcium Channel
Potassium Channel
IRAK
ERK
JNK
NF-κB
Akt
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Trimebutine (Standard) is the analytical standard of Trimebutine (HY-B0380). This product is intended for research and analytical applications. Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
-
- HY-147332
-
|
Liposome
|
Neurological Disease
|
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-147332
-
|
Drug Delivery
|
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10476
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 2 (compd 2) is a myostatin inhibitor with a Kd of 35.9 nM. Myostatin inhibitory peptide 2 can be used for researches of muscle atrophic disorders .
|
-
- HY-P10242
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 7 is a 23 amino acids peptide, which is derived from amino acids 21 to 43 of the mouse myostatin prodomain. Myostatin inhibitory peptide 7 inhibits myostatin with a Kd of 29.7 nM. Myostatin inhibitory peptide 7 can be used for researches of muscle atrophic disorders .
|
-
- HY-P10476A
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 2 (compd 2) TFA is a myostatin inhibitor with a Kd of 35.9 nM. Myostatin inhibitory peptide 2 TFA can be used for researches of muscle atrophic disorders .
|
-
- HY-P10242A
-
|
TGF-beta/Smad
|
Others
|
Myostatin inhibitory peptide 7 TFA is a 23 amino acids peptide, which is derived from amino acids 21 to 43 of the mouse myostatin prodomain. Myostatin inhibitory peptide 7 TFA inhibits myostatin with a Kd of 29.7 nM. Myostatin inhibitory peptide 7 TFA can be used for researches of muscle atrophic disorders .
|
-
- HY-P2436
-
|
Neurokinin Receptor
|
Neurological Disease
|
L-659837 is a NK2 receptor antagonist, and can antagonize GR 64349 (HY-P1278)-induced contraction. L-659837 can be used for study of urinary bladder disorders .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0740S3
-
|
Cyclobenzaprine-d3-1 hydrochloride (MK130-d3-1 hydrochloride) is the deuterium labeled Cyclobenzaprine hydrochloride (HY-B0740). Cyclobenzaprine (MK130) hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Additionally, Cyclobenzaprine hydrochloride has antiprotozoal activity. Additionally, Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases
|
-
-
- HY-B0380S2
-
|
Trimebutine-d3 hydrochloride is deuterium labeled Trimebutine hydrochloride. Trimebutine hydrochloride is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine hydrochloride inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine hydrochloride also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine hydrochloride also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine hydrochloride also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
-
- HY-B0380S1
-
|
Trimebutine-d5 fumarate is deuterium labeled Trimebutine fumarate. Trimebutine fumarate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine fumarate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine fumarate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine fumarate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine fumarate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-147332
-
|
|
Cationic Lipids
|
TCL053 is an ionizable lipid carrier and used to introduce active components, in particular nucleic acids, into cells with excellent efriciency. TCL053, together with DPPC (Dipalmitoylphosphatidylcholine), PEG-DMG (Polyethylene glycoldimyristoyl glycerol), and cholesterol, forms lipid nanoparticle (LNP) which is able to deliver Cas9 mRNA and sgRNA into skeletal muscle .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: